GSK to cut up to 1,217 jobs in Belgium

· Health · Belgium · United Kingdom

GSK will cut as many as 1,217 positions from its Belgian sites, the company said, as part of a cost-cutting drive that CEO Luke Miels outlined in July. The redundancies are the latest step in the British drugmaker's effort to trim spending across its global manufacturing and research footprint, and they land on a Belgian workforce that has long handled work for the company's vaccines and specialty medicines. GSK framed the move as a proposed restructuring; under Belgian law, the company must consult with unions and works councils before the cuts take effect, so the final number and timing could still shift. The announcement continues a wave of layoffs across large pharmaceutical companies as patent expirations on key products force them to redirect money toward pipelines and new launches.

Why it matters：Large-cap pharma layoffs in high-cost European manufacturing hubs are accelerating as patent cliffs force spending toward pipelines, a trend that affects suppliers, unions and local economies across the sector.

Key points

  • The cuts affect GSK sites in Belgium and could reach 1,217 workers.
  • CEO Luke Miels announced the cost-cutting initiative in July.
  • The plan must go through Belgian union and works-council consultation before taking effect.

Sources (original reporting)

More stories from this day